Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 267

1.

Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.

Thewes V, Simon R, Schroeter P, Schlotter M, Anzeneder T, Büttner R, Benes V, Sauter G, Burwinkel B, Nicholson RI, Sinn HP, Schneeweiss A, Deuschle U, Zapatka M, Heck S, Lichter P.

Cancer Res. 2015 Feb 15;75(4):720-31. doi: 10.1158/0008-5472.CAN-14-0652. Epub 2015 Feb 2.

PMID:
25643697
2.

A good drug made better: the fulvestrant dose-response story.

Robertson JF, Lindemann J, Garnett S, Anderson E, Nicholson RI, Kuter I, Gee JM.

Clin Breast Cancer. 2014 Dec;14(6):381-9. doi: 10.1016/j.clbc.2014.06.005. Epub 2014 Jun 24.

PMID:
25457991
3.

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.

Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.

Breast Cancer Res. 2014 Jan 23;16(1):R12. doi: 10.1186/bcr3604.

4.

Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells.

McCloy RA, Shelley EJ, Roberts CG, Boslem E, Biden TJ, Nicholson RI, Gee JM, Sutherland RL, Musgrove EA, Burgess A, Butt AJ.

Br J Cancer. 2013 Dec 10;109(12):3034-41. doi: 10.1038/bjc.2013.693. Epub 2013 Oct 31.

5.

Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.

Lazaro G, Smith C, Goddard L, Jordan N, McClelland R, Barrett-Lee P, Nicholson RI, Hiscox S.

Endocr Relat Cancer. 2013 Aug 28;20(5):691-704. doi: 10.1530/ERC-13-0019. Print 2013 Oct.

6.

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

Browne BC, Hochgräfe F, Wu J, Millar EK, Barraclough J, Stone A, McCloy RA, Lee CS, Roberts C, Ali NA, Boulghourjian A, Schmich F, Linding R, Farrow L, Gee JM, Nicholson RI, O'Toole SA, Sutherland RL, Musgrove EA, Butt AJ, Daly RJ.

FEBS J. 2013 Nov;280(21):5237-57. doi: 10.1111/febs.12441. Epub 2013 Aug 19.

PMID:
23876235
7.

BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.

Stone A, Cowley MJ, Valdes-Mora F, McCloy RA, Sergio CM, Gallego-Ortega D, Caldon CE, Ormandy CJ, Biankin AV, Gee JM, Nicholson RI, Print CG, Clark SJ, Musgrove EA.

Mol Cancer Ther. 2013 Sep;12(9):1874-85. doi: 10.1158/1535-7163.MCT-13-0012. Epub 2013 Jul 16.

8.

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.

Robertson JF, Dixon JM, Sibbering DM, Jahan A, Ellis IO, Channon E, Hyman-Taylor P, Nicholson RI, Gee JM.

Breast Cancer Res. 2013 Mar 5;15(2):R18. doi: 10.1186/bcr3393.

9.

ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.

Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F, Launchbury R, Statham AL, Armstrong N, Alles MC, Young A, Egger A, Au W, Piggin CL, Evans CJ, Ledger A, Brummer T, Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Clark SJ, Carroll JS, Ormandy CJ.

PLoS Biol. 2012;10(12):e1001461. doi: 10.1371/journal.pbio.1001461. Epub 2012 Dec 27.

10.

Pro-metastatic tumor-stroma interactions in breast cancer.

Gangadhara S, Barrett-Lee P, Nicholson RI, Hiscox S.

Future Oncol. 2012 Nov;8(11):1427-42. doi: 10.2217/fon.12.134. Review.

PMID:
23148616
11.

Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.

Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, Poghosyan Z, Nicholson RI, Barrett-Lee P, Gee J.

BMC Cancer. 2012 Oct 6;12:458. doi: 10.1186/1471-2407-12-458.

12.

Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine.

White AW, Carpenter N, Lottin JR, McClelland RA, Nicholson RI.

Eur J Med Chem. 2012 Oct;56:246-53. doi: 10.1016/j.ejmech.2012.08.022. Epub 2012 Aug 24.

PMID:
22995819
13.

Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.

Stone A, Valdés-Mora F, Gee JM, Farrow L, McClelland RA, Fiegl H, Dutkowski C, McCloy RA, Sutherland RL, Musgrove EA, Nicholson RI.

PLoS One. 2012;7(7):e40466. doi: 10.1371/journal.pone.0040466. Epub 2012 Jul 10.

14.

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA.

Mol Cancer Ther. 2012 Jul;11(7):1488-99. doi: 10.1158/1535-7163.MCT-11-0963. Epub 2012 May 7.

15.

Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7.

Taylor KM, Hiscox S, Nicholson RI, Hogstrand C, Kille P.

Sci Signal. 2012 Feb 7;5(210):ra11. doi: 10.1126/scisignal.2002585.

16.

Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.

Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, Emeribe UA, Anderson E, Sapunar F, Finlay P, Nicholson RI, Bines J, Harbeck N.

Breast Cancer Res Treat. 2012 May;133(1):237-46. doi: 10.1007/s10549-011-1947-7.

PMID:
22286314
17.

erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.

Knowlden JM, Gee JM, Barrow D, Robertson JF, Ellis IO, Nicholson RI, Hutcheson IR.

Breast Cancer Res. 2011 Sep 22;13(5):R93. doi: 10.1186/bcr3018.

18.

A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer.

Habashy HO, Powe DG, Abdel-Fatah TM, Gee JM, Nicholson RI, Green AR, Rakha EA, Ellis IO.

Histopathology. 2012 May;60(6):854-63. doi: 10.1111/j.1365-2559.2011.03912.x. Epub 2011 Sep 10. Review.

PMID:
21906125
19.

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.

Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE, Knowlden JM, Nicholson RI, Gee JM.

Breast Cancer Res. 2011 Mar 11;13(2):R29. doi: 10.1186/bcr2848.

20.

Therapeutic targeting of tumor-stroma interactions.

Hiscox S, Barrett-Lee P, Nicholson RI.

Expert Opin Ther Targets. 2011 May;15(5):609-21. doi: 10.1517/14728222.2011.561201. Epub 2011 Mar 10. Review.

PMID:
21388336
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk